Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab    GEN   DK0010272202

GENMAB

(GEN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Genmab : A good level to buy

share with twitter share with LinkedIn share with facebook
share via e-mail
02/07/2019 | 05:42am EST
long trade
Live
Entry price : 962DKK | Target : 1020DKK | Stop-loss : 928.7DKK | Potential : 6.03%
Shares in Genmab show a positive technical chart pattern over the medium term, which suggests that the rising trend should be followed.
Investors have an opportunity to buy the stock and target the DKK 1020.
Chart GENMAB
Duration : Period :
Genmab Technical Analysis Chart | MarketScreener
Full-screen chart
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has poor fundamentals for a short-term investment strategy.

Strengths
  • The close medium term support offers good timing for purchasing the stock.
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Historically, the company has been releasing figures that are above expectations.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 46.74 times its estimated earnings per share for the ongoing year.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Subsector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
GENMAB-5.01%9 438
GILEAD SCIENCES6.11%85 858
VERTEX PHARMACEUTICALS12.08%47 462
REGENERON PHARMACEUTICALS9.37%44 554
SAREPTA THERAPEUTICS INC26.87%9 013
NEUROCRINE BIOSCIENCES, INC..18.40%7 679
BLUEBIRD BIO INC35.08%7 345
LOXO ONCOLOGY INC67.53%7 184
EXELIXIS, INC.13.37%6 667
PEPTIDREAM INC16.39%5 449
BIOCON LTD2.03%5 331
Autres valeurs du secteur

Anaïs Lozach
© Zonebourse.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (DKK)
Sales 2018 2 892 M
EBIT 2018 1 360 M
Net income 2018 1 276 M
Finance 2018 5 976 M
Yield 2018 -
P/E ratio 2018 49,50
P/E ratio 2019 34,36
EV / Sales 2018 19,5x
EV / Sales 2019 13,8x
Capitalization 62 359 M
Upcoming event on GENMAB
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 1 281  DKK
Spread / Average Target 26%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Mats Gunnar Pettersson Chairman
Michael K. Bauer SVP, Head-Operations, Research & Development
David Andrew Eatwell Chief Financial Officer & Executive Vice President
Anders Gersel Pedersen Deputy Chairman